Lumida
/CV
⌘K
CV

CV

CV
$6.71USD↑+5.01%+0.32 today

MARKET CAP

335.3M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$6 – $7

52W RANGE

$3
$15

AI Summary

Stalk
StalkMedium

CV is in a Stage 2 advancing phase with a bullish medium-term bias reinforced by higher highs and higher lows, rising short-term EMAs, and low transition risk. Price is currently extended above key EMAs without a clear pullback, so execution should be deferred into structural support zones rather than pursued on the current extension.

  • ↑167k patients scanned with Capsule Chem Plus, showing robust adoption.
  • ↑AI integration expected to cut wait times and boost workflow efficiency.
  • ↓Net loss of $7.9M in Q3 2025; operating loss widened to $8.4M in Q1 2026.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

CapsoVision, Inc. (NASDAQ: CV) is an emerging player in the gastrointestinal (GI) diagnostic market, specializing in advanced imaging technologies and ingestible capsule platforms for non-invasive screening of gastrointestinal diseases, including cancers. The company is focused on innovating with AI technology to enhance diagnostic accuracy and accessibility, positioning itself favorably within a healthcare environment that increasingly demands patient-friendly diagnostic solutions.

Bull says

  • ↑167k patients scanned with Capsule Chem Plus, showing robust adoption.
  • ↑AI integration expected to cut wait times and boost workflow efficiency.
  • ↑$17.9M cash (post $14M raise) secures R&D and market expansion.
  • ↑Gen 2 Colon capsule submission planned next year to drive revenue.
  • ↑Benchmark maintains Speculative Buy rating with $10 price target.
  • ↑Book-to-price ratio of 0.52 and moderate dividend yield indicate value.

Bear says

  • ↓Net loss of $7.9M in Q3 2025; operating loss widened to $8.4M in Q1 2026.
  • ↓Gross margin fell from 54% to 48% as tariffs increased costs.
  • ↓Operating expenses rose by $1.5M YoY, driven by higher R&D spend.
  • ↓Negative earnings revisions reflect analyst skepticism on profitability outlook.
  • ↓High stock volatility causes significant price swings and investor risk.
  • ↓Low institutional confidence shown by minimal 13F ownership and weak quality score.

Investment themes with CV

Medical Devices↑ +0.68%

Devices and instruments for medical treatment

MEDP · RDNT · OPCH

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-15-2026neutral

Transcript signals

Bull points

  • Capsule imaging remains focused on advancing earlier, more accurate, and more accessible detection of gastrointestinal disease for patients worldwide.
  • We are working toward a unified, ingestible capsule platform capable of screening for multiple cancers, including esophageal, gastric, pancreatic, liver, and colorectal through a single non-invasive procedure enabled by advanced imaging and AI.
  • During the quarter, we also secured key renewals for large GI networks, including Indiana University Health Systems, Providence Health Systems, and GastroHealth, which we believe reinforces the value of our platform and the strength of our long-term customer relationships.

Bear points

  • Operating expenses were $8.4 million, an increase of $1.5 million compared to the prior year period. This increase was driven primarily by continued investment in our pipeline, including development work related to the next generation imaging sensor under our agreement with Canon, as well as clinical trial activities supporting the CapsoCam Colon Gen 2 program.
  • Total revenue was $2.8 million, consistent with prior year period. While the number of capsules sold was modestly lower year over year, this was offset by a slight increase in ASP.
  • And, as Johnny noted earlier, gross profit for the quarter was $1.3 million, with a gross margin of 48%, compared to 54% in the first quarter of 2025. The change in gross margin was primarily due to tariffs impacting our cost of goods sold.
Read full transcript analysis ›